Alligator Bioscience expands its Board of Directors with the appointment of Staffan Encrantz and Denise Goode
Lund, Sweden, May 9, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Staffan Encrantz and Denise Goode as members of the company's Board of Directors. Mr. Encrantz is the founder and Chairman of Allegro Investment Fund, a $750 million fund which has been investing in companies across a number of industries for 30 years and is also a major shareholder in Alligator Bioscience. Ms. Goode has more than 25 years of experience in business leadership and innovation, having held a number of senior executive and board-level positions in the pharmaceutical and life science industries, including at AstraZeneca.
"It's a great pleasure to welcome Staffan and Denise to our Board of Directors," said Anders Ekblom, Chairman of Board of Directors of Alligator Bioscience. "Staffan is a hugely experienced investor having led the growth and development of numerous companies, including start-ups and established businesses, over the last 30 years. Since 2015, he has taken a great interest in Alligator Bioscience, and we are delighted to have him assume a formal leadership role in the company. Denise brings with her a huge amount of insight and experience with a deep understanding of the pharmaceutical industry as well as financing, fundraising and business development. Their appointments will further strengthen the leadership of the company and underline our commitment to our mission of developing antibody-based treatments for cancer while creating outstanding value for our shareholders."
The new appointees will bring the number of Board members at Alligator Bioscience to eight, including the Chairman.
"I see great potential in Alligator Bioscience, not only in the potential of mitazalimab to revolutionize the treatment paradigm in metastatic pancreatic cancer but also of Alligator’s broad product portfolio and its drug development platform," said Staffan Encrantz, Board Member of Alligator Bioscience. "The company is rightly focused on improving the balance between R&D and commercialization and I look forward to working with Alligator's excellent management team to help them achieve this."
"I am very pleased to be joining the Board at Alligator Bioscience at a very important time for the company," said Denise Goode, Board Member of Alligator Bioscience. "Alligator's innovative technologies have the chance to make a real contribution to the future of cancer therapy and a difference to those suffering from these hard-to-treat conditions."
About Staffan Encrantz
Staffan Encrantz is the founder and Chairman of Allegro Investment Fund, based in California, which manages a $750 million investment portfolio. He has actively led investments in a variety of companies over the last 30 years, including 20 years of investing in the life science industry. He has extensive experience in the hedge fund industry and in commercial real estate, especially in Sweden and the U.S. He holds a number of board positions in U.S. and European companies in various industries.
About Denise Goode
Denise Goode is the CEO of QED Life Sciences Limited, a consultancy company advising on and supporting the strategic direction of biotech companies and providing business mentoring to CEOs and senior leaders. Previously, she had a 20-year career with AstraZeneca where she held global senior leadership roles within both finance and commercial activities. She has a Bachelor of Science in Zoology from the University of Manchester and is a Fellow of the Institute of Chartered Accountants in England and Wales.
For further information, please contact:
Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 46-540 82 00
Marie Svensson, CFO
E-mail: marie.svensson@alligatorbioscience.com
Phone: +46 46-540 82 03
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4- 1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.
For more information, please visit alligatorbioscience.com.